These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8539062)

  • 21. Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women.
    Nagata-Kobayashi S; Shimbo T; Fukui T
    J Bone Miner Metab; 2002; 20(6):350-7. PubMed ID: 12434163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits and risks of hormone/estrogen replacement.
    Thomas DJ
    Nurs Clin North Am; 1996 Dec; 31(4):815-25. PubMed ID: 8969341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteoporosis and cardiovascular disease: benefit-risk of hormone replacement therapy.
    Sammartino A; Cirillo D; Mandato VD; Di Carlo C; Nappi C
    J Endocrinol Invest; 2005; 28(10 Suppl):80-4. PubMed ID: 16550729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Swedish gynecologists' and general practitioners' views on the climacteric period: knowledge, attitudes and management strategies.
    Andersson K; Pedersen AT; Mattsson LA; Milsom I
    Acta Obstet Gynecol Scand; 1998 Oct; 77(9):909-16. PubMed ID: 9808379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Estrogen treatment for prevention and therapy of osteoporosis].
    von Werder K
    Fortschr Med; 1997 Oct; 115(29):44-9. PubMed ID: 9445834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
    Skouby SO; Al-Azzawi F; Barlow D; Calaf-Alsina Erdogan Ertüngealp J; Gompel A; Graziottin A; Hudita D; Pines A; Rozenberg S; Samsioe G; Stevenson JC;
    Maturitas; 2005 May; 51(1):8-14. PubMed ID: 15883103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
    Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
    Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Justification for the use of HRT in the long-term prevention of osteoporosis.
    Stevenson JC
    Maturitas; 2005 Jun; 51(2):113-26. PubMed ID: 15917151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compliance considerations with hormone replacement therapy.
    Karakoç B; Erenus M
    Menopause; 1998; 5(2):102-6. PubMed ID: 9689204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Climacteric: concept, consequence and care.
    Taechakraichana N; Jaisamrarn U; Panyakhamlerd K; Chaikittisilpa S; Limpaphayom KK
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S1-15. PubMed ID: 12188398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Postmenopausal osteoporosis].
    László A
    Orv Hetil; 2004 Jan; 145(1):3-13. PubMed ID: 15222134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Knowledge of osteoporosis correlated with hormone therapy use and health status.
    Vytrisalova M; Kubena A; Vlcek J; Palicka V; Hala T; Pavelka K
    Maturitas; 2007 Jan; 56(1):21-9. PubMed ID: 16797149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of exercise training on bone remodeling, insulin-like growth factors, and bone mineral density in postmenopausal women with and without hormone replacement therapy.
    Milliken LA; Going SB; Houtkooper LB; Flint-Wagner HG; Figueroa A; Metcalfe LL; Blew RM; Sharp SC; Lohman TG
    Calcif Tissue Int; 2003 Apr; 72(4):478-84. PubMed ID: 12574871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?
    Stevenson JC;
    Hum Reprod; 2006 Jul; 21(7):1668-71. PubMed ID: 16556675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women.
    Josse RG
    CMAJ; 1996 Oct; 155(7):929-34. PubMed ID: 8837542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits of hormone replacement therapy--overview and update.
    Calaf i Alsina J
    Int J Fertil Womens Med; 1997; 42 Suppl 2():329-46. PubMed ID: 9397382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose hormone replacement therapy: effects on bone.
    Gambacciani M; Monteleone P; Genazzani AR
    Climacteric; 2002 Jun; 5(2):135-9. PubMed ID: 12051108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Alternatives to hormone replacement therapy: raloxifene and tibolone].
    von Holst T
    Z Arztl Fortbild Qualitatssich; 2000 Apr; 94(3):205-9. PubMed ID: 10802895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.